86212-34-2

Usage

Uses

Used in Pharmaceutical Industry:
meso-1,2-Bis(4-chlorophenyl)ethylenediamine, min. 98% is used as a building block for the synthesis of various pharmaceuticals due to its high purity and specific stereochemistry, enabling the production of high-quality and effective drugs.
Used in Agrochemical Industry:
meso-1,2-Bis(4-chlorophenyl)ethylenediamine, min. 98% is used as a key intermediate in the synthesis of agrochemicals, contributing to the development of effective and safe pesticides and other agricultural products.
Used in Organic Synthesis:
meso-1,2-Bis(4-chlorophenyl)ethylenediamine, min. 98% is used as a versatile reagent in organic synthesis, allowing for the creation of a wide range of organic compounds with minimal impurities and specific stereochemical control.
Used in Fine Chemicals Production:
meso-1,2-Bis(4-chlorophenyl)ethylenediamine, min. 98% is used as a crucial component in the production of fine chemicals, including specialty chemicals and high-value compounds for various applications.

InChI:InChI=1/C14H14Cl2N2/c15-11-5-1-9(2-6-11)13(17)14(18)10-3-7-12(16)8-4-10/h1-8,13-14H,17-18H2/p+2/t13-,14+

Upstream product

• 41097-37-4 (1E, 2E)-1,2-bis (4-chlorobenzylidene) hydrazine 
• 3848-36-0 4-chlorobenzaldoxime 
• 115294-32-1 C₂₈H₂₀Cl₄N₂O 
• 104-88-1 4-chlorobenzaldehyde 
• 115294-32-1 4-chloro-benzoic acid-[erythro-4,4'-dichloro-α'-(4-chloro-benzylidenamino)-bibenzyl-α-ylamide] 

Downstream Products

• 86212-33-1 4,5-di(p-chlorophenyl)imidazoline-2-thione 
• 548472-49-7 (4R,5S)-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole 
• 944253-11-6 meso-4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-pyridin-3-yl)-4,5-dihydro-1H-imidazole 
• 1332292-88-2 N-((1S,2R)-1,2-bis(4-chlorophenyl)-2-(pyrrolidin-1-yl)ethyl)benzamide 
• 1332292-87-1 (1S,2R)-1,2-bis(4-chlorophenyl)-2-(pyrrolidin-1-yl)ethanamine 
• 1332292-86-0 N-((1S,2R)-2-(3-(3,5-bis(trifluoromethyl)phenyl)thioureido)-1,2-bis(4-chlorophenyl)ethyl)benzamide 
• 1332292-85-9 C₂₈H₂₃Cl₂N₃O₂ 
• 1332292-75-7 N-((1S,2R)-2-amino-1,2-bis(4-chlorophenyl)ethyl)benzamide 

Relevant academic research and scientific papers

MDM2 DEGRADERS AND USES THEREOF

The present invention relates to compounds and methods useful for the modulation of mouse double minute 2 homolog ("MDM2") protein via ubiquitination and/or degradation by compounds according to the present invention.

Chemoselective Photoredox Synthesis of Unprotected Primary Amines Using Ammonia

Unprotected α-amino carbon radicals are produced as novel intermediates via a transformation that merges acid-promoted N-H imine generation and chemoselective photocatalytic single-electron reduction. Coupling ammonia and aldehydes/ketones allows the generation of primary amines under mild conditions without the need for protecting groups. The key intermediate can be efficiently transformed into primary (di)amines by a formal dimerization, reductive amination via hydrogen atom transfer, and arylation through radical-radical coupling.

Dimer ester micromolecule PROTACs for inducing MDM2 to self-degrade E3 ubiquitin ligase

The invention provides dimer ester micromolecule PROTACs for inducing MDM2 to self-degrade E3 ubiquitin ligase. The structure of the PROTACs is shown in the specification, wherein in a compound (I), L1 is C1-C30 linear or branched alkyl with or without a substituent group, and any carbon atom in L1 is optionally replaced by heteroatom; R1, R2, R3 and R4 are C1-C30 linear or branched alkyl with orwithout a substituent group, C1-C30 aryl with or a without substituent group, C1-C30 linear or branched alkylaryl with or without a substituent group or C1-C30 linear or branched aryl alkyl with or without a substituent group respectively and independently; X1, X2, X3 and X4 are halogen respectively and independently.

Chiral synthesis method for producing cis-imidazoline compounds for pharmaceutical use

This invention provides a method for enantioselective synthesis of cis-imidazolines and related structures through chiral resolution. A chiral acid is used to separate enantiomeric precursors of the cis-imidazolines from a racemic mixture by selective cry

Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents

p53-Murine double minute 2 (MDM2) interaction and histone deacetylases (HDACs) are important targets in antitumor drug development. Inspired by the synergistic effects between MDM2 and HDACs, the first MDM2/HDACs dual inhibitors were identified, which sho

Dimer amide micromolecule PROTACs for inducing MDM2 to self-degrade E3 ubiquitin ligase

The invention provides dimer amide micromolecule PROTACs for inducing MDM2 to self-degrade E3 ubiquitin ligase. The structure of the PROTACs is shown in the specification, wherein in a compound (I), L1 is C1-C30 linear or branched alkyl with or without a substituent group, and any carbon atom in L1 is optionally replaced by heteroatom; R1, R2, R3 and R4 are C1-C30 linear or branched alkyl with orwithout a substituent group, C1-C30 aryl with or without a substituent group, C1-C30 linear or branched alkylaryl with or without a substituent group or C1-C30 linear or branched aryl alkyl with or without a substituent group respectively and independently; X1, X2, X3 and X4 are halogen respectively and independently.

Lipase-catalyzed desymmetrization of meso-1,2-diaryl-1,2-diaminoethanes

The synthesis and enzyme-catalyzed desymmetrization of meso-1,2-diaryl-1,2- diaminoethanes have been investigated. A family of aromatic meso-1,2-diamines, containing different substitution patterns in the aromatic ring, was first prepared and then desymmetrized enantioselectively using lipases as biocatalysts. Selective alkoxycarbonylation of one of the amino groups was achieved using allyl carbonates, isolating the corresponding allyl monocarbamates with moderate to high enantiomeric excess at 45 C. Candida antarctica lipase types A (CAL-A) and B (CAL-B) displayed the best activities and stereopreferences, with a dramatic influence being observed depending on the diamine structure. Non substituted and para-substituted aryldiamines led to the formation of allyl carbamates with good enantiomeric excess, using CAL-A for the less hindered substrates and CAL-B for the more hindered ones. On the other hand meta- and ortho-derivatives afforded low or negligible conversions and selectivities, respectively.

Design, synthesis and CoMFA studies of N1-amino acid substituted 2,4,5-triphenyl imidazoline derivatives as p53-MDM2 binding inhibitors

A series of novel N1-amino-acid substituted 2,4,5-triphenyl imidazoline derivatives was designed and synthesized based on our previous studies. All synthesized target compounds were screened for their p53-MDM2 binding inhibitory activities and anti-proliferative activities against five cancer cell lines. Among them, twelve compounds displayed improved binding inhibitory activities and most compounds showed higher cell growth inhibition activities with IC 50 values in the low micromolar range. Compound 6c exhibited marked p53-MDM2 binding inhibitory activity (IC50 = 0.59 μM) which was eightfold more potent than that of Nutlin-1 (IC50 = 4.78 μM). CoMFA analysis was performed based on obtained biological data and resulted in a statistically significant CoMFA model with high predict abilities (q 2 = 0.645, r2 = 0.979).

Design, synthesis, and biological evaluation of imidazoline derivatives as p53-MDM2 binding inhibitors

Three series of novel imidazoline derivatives were designed, synthesized, and evaluated for their p53-MDM2 binding inhibitory activities, and anti-proliferation activities against PC3, A549, KB, and HCT116 cancer cell lines. Five of the tested compounds showed enhanced p53-MDM2 binding inhibitory potency and anti-proliferation activities in comparison with that of Nutlin-1. Flow cytometric analysis indicated that compound 7c, one of the most potent p53-MDM2 binding inhibitors with a Ki value of 0.6 μM, showed its ability to arrest cell cycle progression.

Substituted Dihydroimidazoles and their Use in the Treatment of Tumors

The invention relates to dihydroimidazoles of formula rac-(I), wherein the radicals and symbols are as defined herein; their use as inhibitors of the interaction of the MDM2 protein with a p53-like peptide, new pharmaceutical formulations comprising said compounds, said compounds for use in the therapeutic treatment of warm-blooded animals, especially humans, their use in the treatment of proliferative diseases or for the manufacture of pharmaceutical formulations useful in the treatment of proliferative diseases that respond to modulation of the interaction of the MDM2 protein with a p53-like peptide, a pharmaceutical formulation e.g. useful in the treatment of proliferative diseases that respond to modulation of the interaction of the MDM2 protein with a p53-like peptide comprising said compound, methods of treatment comprising administration of said compounds to a warm-blooded animal, and/or processes for the manufacture of said compounds.